Redeye initiates coverage of Q-linea

tis, maj 14, 2019 07:57 CET

Q-linea is about 12 months from launching ASTar - a diagnostic system for rapid phenotypic antibiotic susceptibility testing (AST). The share’s underperformance indicates that investors have yet to grasp the technology’s paradigm-shifting impact and the product portfolio’s high sales potential.

Read more and download the research update: http://bit.ly/2VAuTkp

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/